Structure

InChI Key BLSQLHNBWJLIBQ-OZXSUGGESA-N
Smile CC(C)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4cncn4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
InChI
InChI=1S/C26H31Cl2N5O3/c1-19(2)31-9-11-32(12-10-31)21-4-6-22(7-5-21)34-14-23-15-35-26(36-23,16-33-18-29-17-30-33)24-8-3-20(27)13-25(24)28/h3-8,13,17-19,23H,9-12,14-16H2,1-2H3/t23-,26-/m0/s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C26H31Cl2N5O3
Molecular Weight 532.47
AlogP 4.46
Hydrogen Bond Acceptor 8.0
Hydrogen Bond Donor 0.0
Number of Rotational Bond 8.0
Polar Surface Area 64.88
Molecular species NEUTRAL
Aromatic Rings 3.0
Heavy Atoms 36.0

Pharmacology

Action Mechanism of Action Reference
INHIBITOR Cytochrome P450 51 inhibitor PubMed PubMed DailyMed

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Candidiasis, Vulvovaginal 3 D002181 ClinicalTrials
Vaginitis 0 D014627 ClinicalTrials

Related Entries

MCS

Scaffolds

Side Effects from Label

Adverse Reactions

System Organ Classification (SOC)
Relative Frequency (%)
General disorders and administration site conditions
17.91
Injury, poisoning and procedural complications
13.65
Reproductive system and breast disorders
11.88
Product issues
8.69
Skin and subcutaneous tissue disorders
7.8
Vascular disorders
5.14
Infections and infestations
4.61
Gastrointestinal disorders
4.43
Musculoskeletal and connective tissue disorders
3.72
Nervous system disorders
3.72
Pregnancy, puerperium and perinatal conditions
2.66
Immune system disorders
2.3
Respiratory, thoracic and mediastinal disorders
2.3

Cross References

Resources Reference
CAS NUMBER 67915-31-5
ChEBI 82980
ChEMBL CHEMBL1306
DrugBank DB00251
EPA CompTox DTXSID2045498
FDA SRS 0KJ2VE664U
Human Metabolome Database HMDB0014396
KEGG C08080
PharmGKB PA164768834
PubChem 480953
SureChEMBL SCHEMBL23165
ZINC ZINC000003873936